Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).

  title={Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).},
  author={Clive L Yeates},
  journal={Current opinion in investigational drugs},
  volume={3 10},
  • Clive L Yeates
  • Published 2002 in Current opinion in investigational drugs
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis. Phase III trials for the treatment of visceral leishmaniasis had been initiated by March 2002, at which time GlaxoSmithKline hoped to file an MAA in 2003. By 1999, the compound had also undergone phase I trials in HIV-infected individuals for the treatment of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 17 extracted citations

Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development

The open medicinal chemistry journal • 2011
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…